The US and Canada have healthcare, life science and medical device industries that are complex and interconnected.

On March 6, President Donald Trump instituted a 25 percent ad valorem rate of duty on goods imported from Canada under the International Emergency Economic Powers Act.[1] The tariffs will not be implemented on goods that comply with the United States-MexicoCanada Agreement until April 2.[2] In turn, Canada has announced a $155 billion tariff package on the US.[3]

Download the full Law360 article, "Mitigating Tariff Risks For Healthcare In US And Canada."



Contacts

Jeff Wurzburg
Jeff Wurzburg
Partner
Email
jeff.wurzburg@nortonrosefulbright.com
T: +1 210 270 9338
Vanessa Grant
Vanessa Grant
Senior Partner
Email
vanessa.grant@nortonrosefulbright.com
T: +1 416 216 4056

Practice areas:

Industry:

Recent publications

Blog

Squaring the circle: fiduciary duties v economic growth

This is the first in a series of blogs about the Government’s Mansion House reforms, and its goal to get pension schemes doing more for the UK economy.

United Kingdom | April 24, 2025

Financial institutions

Publication

Distress signals – Cooperation agreements or mergers to the rescue in times of crisis?

The current volatile and unpredictable economic climate creates challenges for businesses.

Global | April 23, 2025

Merger control
Navigating international trade and tariffs

Publication

Navigating international trade and tariffs

Recent tariffs and other trade measures have transformed the international trade landscape, impacting almost every sector, region and business worldwide.

Global | April 21, 2025

International trade
Site search

Subscribe and stay up to date with the latest legal news, information and events . . .

Register now